Natera Revenue and Competitors
Estimated Revenue & Valuation
- Natera's estimated annual revenue is currently $564.8M per year.
- Natera's estimated revenue per employee is $145,878
- Natera's total funding is $404.1M.
- Natera's current valuation is $6.4B. (January 2022)
Employee Data
- Natera has 3872 Employees.
- Natera grew their employee count by 6% last year.
Natera's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | Chief Compliance & Privacy Officer | Reveal Email/Phone |
3 | Chief Information Security Officer (CISO) | Reveal Email/Phone |
4 | Global VP, Biopharma | Reveal Email/Phone |
5 | Chief Accounting Officer | Reveal Email/Phone |
6 | CEO | Reveal Email/Phone |
7 | VP | Reveal Email/Phone |
8 | VP, Patient Services | Reveal Email/Phone |
9 | VP Lab Affairs | Reveal Email/Phone |
10 | VP Research And Development, Oncology | Reveal Email/Phone |
Natera Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $434.8M | 1865 | -14% | $2B | $2.7B |
#2 | $76.6M | 669 | -7% | $574.9M | N/A |
#3 | $343.9M | 3176 | 7% | $550M | $7.9B |
#4 | $218.4M | 299 | -63% | $791M | $974.7M |
#5 | $37.9M | 265 | 29% | N/A | N/A |
#6 | $31.5M | 203 | 1% | N/A | N/A |
What Is Natera?
Natera is a genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its cloud-based Constellation™ software system. Tests include the Spectrum™ pre-implantation genetic test for embryo selection during IVF; the Anora™ miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama™ non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.
keywords:Biotechnology$404.1M
Total Funding
3872
Number of Employees
$564.8M
Revenue (est)
6%
Employee Growth %
$6.4B
Valuation
N/A
Accelerator
Natera News
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease...
Bragar Eagel & Squire, P.C. Is Investigating Natera, Mullen, Arqit, and Netflix and Encourages Investors to Contact the Firm.
Natera is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. We aim to make personalized...
AUSTIN, Texas, Oct. 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA testing, today announced that it will release results for its third quarter ended September 30, 2021, after the market close on November 4, 2021. Natera will ...
AUSTIN, Texas, Oct. 18, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, announced the launch and availability of its Prospera donor-derived cfDNA (dd-cfDNA) transplant assessment test for lung transplant recipient ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $523.8M | 4685 | 3% | N/A |
#2 | $2130M | 6770 | N/A | N/A |
#3 | $1521.4M | 7762 | 5% | N/A |
#4 | $2260M | 7913 | 5% | N/A |
#5 | $2260M | 7913 | 5% | N/A |